MindWalk (NASDAQ:HYFT) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

MindWalk (NASDAQ:HYFT) announced its quarterly earnings data on Thursday. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02), Zacks reports. MindWalk had a negative return on equity of 56.75% and a negative net margin of 145.58%.The firm had revenue of $3.00 million during the quarter, compared to the consensus estimate of $3.50 million.

MindWalk Trading Down 6.5%

Shares of HYFT traded down $0.09 during midday trading on Friday, hitting $1.23. 298,112 shares of the company’s stock traded hands, compared to its average volume of 605,073. The company has a quick ratio of 4.09, a current ratio of 4.19 and a debt-to-equity ratio of 0.18. The firm has a market cap of $56.55 million, a PE ratio of -2.04 and a beta of 0.58. MindWalk has a 1 year low of $0.32 and a 1 year high of $3.25. The company’s fifty day moving average is $1.54.

Wall Street Analyst Weigh In

HYFT has been the subject of several research reports. UBS Group reissued a “buy” rating on shares of MindWalk in a research report on Friday. Zacks Research raised shares of MindWalk from a “strong sell” rating to a “hold” rating in a research note on Monday, February 16th. Weiss Ratings started coverage on MindWalk in a report on Wednesday, January 14th. They issued a “sell (d-)” rating for the company. Finally, HC Wainwright restated a “buy” rating on shares of MindWalk in a report on Friday. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

Institutional Investors Weigh In On MindWalk

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC increased its holdings in MindWalk by 147.3% in the 4th quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock worth $293,000 after acquiring an additional 96,018 shares in the last quarter. Bridgeway Capital Management LLC purchased a new stake in shares of MindWalk during the fourth quarter worth about $91,000. XTX Topco Ltd raised its position in shares of MindWalk by 118.6% during the 4th quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock worth $149,000 after purchasing an additional 44,331 shares during the last quarter. Virtu Financial LLC purchased a new position in MindWalk in the 4th quarter valued at about $51,000. Finally, Bank of Montreal Can lifted its stake in MindWalk by 81.0% in the 4th quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock valued at $100,000 after buying an additional 24,500 shares in the last quarter. 6.70% of the stock is currently owned by hedge funds and other institutional investors.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.